Therapeutic effect of proaftol in treatment of recurrent aphthous stomatitis (original) (raw)
Related papers
Essentials of recurrent aphthous stomatitis (Review)
Biomedical Reports, 2019
Recurrent aphthous stomatitis (RAS), also known as canker sores, is the most common disease of the oral mucosa. Unlike caries and periodontal disease, patients with RAS are unable to prevent it. The clinical picture of RAS is characterized by recurrent episodes of solitary or multiple painful ulcerations without association with systemic diseases. The objective of this review is to present the essential characteristics of RAS, including its definition, pathogenesis, clinical and microscopic characteristics, proposed experimental models and recommended pharmacological management. This understanding can serve as a theoretical framework for research proposals
International Journal of Contemporary Medical Research [IJCMR]
Introduction: Recurrent aphthous stomatitis (RAS) is a common condition of the mucosa of oral cavity characterized by recurrent attacks of small, round or oval, painful affecting 5-25% of the general population and rarely involves genital region. These lesions occur most commonly on the nonkeratinized epithelium of oral cavity and ulcers heal within a period of 10-14 days with characteristic feature of pain causing difficulty on chewing, swallowing, and/or speaking. So, the purpose of present study was to evaluate the effectiveness of Amlexanox 5% and Triamcinolone 0.1% for the treatment of recurrent aphthous ulcers. Material and Methods: This double-blinded randomized clinical study done in the Department of Oral Medicine And Radiology, Government dental college Srinagar includes 36 patients suffering from recurrent aphthous ulcers aged between 25 and 55 years old and, having minor aphthous ulcers not more than 48 hours old. Group-1 was administered with Triamcinolone 0.1% (Kenocort 0.1% oral paste, Abbort Laboratories Chicago USA), while the group-2 was administered with Amlexanox 5% (Lexanox 5% oral paste, macleods Pharmaceuticals India). The patients used these pastes four times daily for 7 days. The patients were followed at days 0, 3, 5 and 7 and scores were assessed using visual analog scale.
Recurrent Aphthous Stomatitis: Towards Evidence-Based Treatment?
Current Oral Health Reports, 2015
Recurrent aphthous stomatitis is one of the most common oral mucosal diseases seen by dental professionals, and yet its etiology remains unclear, and its management based on less than robust evidence. The literature remains confused because of the lack of clarity in diagnosis and the lack of a standardized ulcer severity scoring system and agreed outcome measures. However, recent literature is encouraging in meeting these aims. There is agreement that RAS is a localized mucosal disease not secondary to systemic disease and therefore distinguishable from over forty other types of oral ulcers. Disease severity scores have been introduced and outcome measures have become more standardized. RAS appears to be an auto-immune disease directed at epitopes of heat shock proteins while most recent work on etiology has focused on cytokines and genetics. Pro-inflammatory cytokines including TNFa and IL-6 and IL-17 are raised in RAS and TNF inhibitors can inhibit episodes of ulceration. Many local anti-inflammatory agents will help ulcers heal, and local steroids remain the treatment of choice. Some systemic drugs have evidence based data indicating efficacy at preventing new ulcers including colchicine, prednisolone, thalidomide, pentoxyfilline and dapsone. The field would benefit from further trials combining local and systemic therapy using defined outcome measures.
BMC Oral Health, 2016
Background: Recurrent Aphthous stomatitis (RAS) is a prevalent ulcerative and painful disorder of the oral cavity with unknown etiology and for which no efficient treatment is currently available. The present study aimed to evaluate the safety and the efficacy of AphtoFix®, a new mouth ulcer cream that was developed to help treat RAS. Prior to launching the product on the market, two initial safety assessment studies were performed. Subjects and methods: In a first study, the in vitro biocompatibility of AphtoFix® was evaluated on reconstructed human gingival tissue models according to ISO guidelines 10993. In a second study, the tolerability of AphtoFix® was evaluated in 20 subjects during a 4-weeks daily application in the mouth. The third study investigated both the safety and efficacy of AphtoFix® treatment on 19 patients suffering from RAS. This study was done in compliance with the Helsinki Declaration. Results: The results of in vitro biocompatibility study showed that AphtoFix® mouth ulcer cream did not induce any detectable cytotoxicity and irritation. These observations were confirmed in the 4 weeks tolerability study where no undesired of adverse reactions were noticed. The results of the post-market clinical efficacy study demonstrated a clear reduction in ulcer size from baseline after 3 days treatment (p < 0.05). Pain intensity reduction was also observed in all subjects. Conclusion: The application of AphtoFix® did not induce any undesired skin or mucosa reactions. These initial findings demonstrate that AphtoFix® is safe and efficient in reducing ulcer size and decreasing the pain intensity induced by ulcers.
Guidelines for Diagnosis and Treatment of Recurrent Aphthous Stomatitis for Dental Practitioners
Indian Journal of Forensic Medicine & Toxicology, 2020
Recurrent aphthous stomatitis (RAS) is one of the frequent clinical oral diseases causing painful ulceration in the oral cavity. It is easy to define the clinical features and characteristics of this disease, etiology and pathogenesis remains unclear. As a result, the treatment options are still inadequate with the ability to reduce the duration, healing time, rate of recurrence and conclusive intervention. The review article aims to discuss the pathogenesis, clinical features, different treatment modalities and updates that are currently available and offer the clinician a clear and detailed picture of how to deal with RAS in an appropriate manner.
Recurrent aphthous stomatitis: a review
Journal of Oral Pathology & Medicine, 2012
Recurrent aphthous stomatitis (RAS), also known as canker sores, is the most common disease of the oral mucosa. Unlike caries and periodontal disease, patients with RAS are unable to prevent it. The clinical picture of RAS is characterized by recurrent episodes of solitary or multiple painful ulcerations without association with systemic diseases. The objective of this review is to present the essential characteristics of RAS, including its definition, pathogenesis, clinical and microscopic characteristics, proposed experimental models and recommended pharmacological management. This understanding can serve as a theoretical framework for research proposals. Contents 1. Introduction 2. Differential diagnosis and epidemiology 3. Pathogenesis 4. Clinical characteristics 5. Disease phases 6. Microscopic characteristics 7. Experimental models 8. Treatment 9. Conclusions
Guidelines for Diagnosis and Management of Aphthous Stomatitis
The Pediatric Infectious Disease Journal, 2007
Aphthous ulcers are the most common oral mucosal lesions in the general population. These often are recurrent and periodic lesions that cause clinically significant morbidity. Many suggestions have been proposed but the etiology of recurrent aphthous stomatitis (RAS) is unknown. Several precipitating factors for aphthous ulcers appear to operate in subjects with genetic predisposition. An autoimmune or hypersensitivity mechanism is widely considered possible. Sometimes aphthous ulcers can be the sign of systemic diseases, so it is essential to establish a correct diagnosis to determine suitable therapy. Before initiating medications for aphthous lesions, clinicians should determine whether well-recognized causes are contributing to the disease and these factors should be corrected.
Clinical study of 200 patients with recurrent aphthous stomatitis
Gaceta medica de Mexico
Recurrent aphthous stomatitis (RAS) affects approximately 20% of the general population. Its etiology is still unknown. To analyze this entity's clinical features. Data such as age, gender, family history of RAS, age at first episode onset, prodromal symptoms, number, size, morphology and localization of lesions, RAS clinical form, annual rate of recurrence, predisposing factors, symptoms and time for symptoms and lesions disappearance were assessed in 200 patients with RAS. Patients had RAS minor forms. Main clinical characteristics were family history of RAS (89%), first episode at ≥ 10 years of age (69%), prodromal symptoms (66%), one lesion per episode (63%), < 0.5 cm lesions (64%), rounded morphology (55%), localization at the tongue (27%), 3 recurrent episodes per year (36%), stress as predisposing factor (34%), symptom disappearance in 2 days (54%) and healing of lesions in 8 days (40%). Even when RAS is a common disorder of the oral mucosa, there is no curative treatm...
Practical aspects of management of recurrent aphthous stomatitis
Journal of The European Academy of Dermatology and Venereology, 2007
Treatment of recurrent aphthous stomatitis (RAS) remains, to date, empirical and non-specific. The main goals of therapy are to minimize pain and functional disabilities as well as decrease inflammatory reactions and frequency of recurrences. Locally, symptomatically acting modalities are the standard treatment in simple cases of RAS. Examples include topical anaesthetics and analgesics, antiseptic and anti-phlogistic preparations, topical steroids as cream, paste or lotions, antacids like sucralfate, chemically stable tetracycline suspension, medicated toothpaste containing the enzymes amyloglucosidase and glucoseoxidase in addition to the well-known silver nitrate application. Dietary management supports the treatment. In more severe cases, topical therapies are again very useful in decreasing the healing time but fail to decrease the interval between attacks. Systemic immunomodulatory agents, like colchicine, pentoxifylline, prednisolone, dapsone, levamisol, thalidomide, azathioprine, methotrexate, cyclosporin A, interferon alpha and tumour necrosis factor (TNF) antagonists, are helpful in resistant cases of major RAS or aphthosis with systemic involvement.